{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-25-018145","form_type":"8-K","ticker":"KAPA","cik":"0001962011","company_name":"Kairos Pharma, LTD.","filed_at":"2025-10-15T23:59:59+00:00","discovered_at":"2026-05-14T18:02:41.163935+00:00","generated_at":"2026-05-17T03:47:37.824480+00:00","sec_items":["5.02","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"confidence":"high","headline":"Kairos Pharma grants $950K RSUs to executives; $227.5K cash bonuses for FY2024","bullets":["Total RSU grant value $950K at $1.31/share, vesting Oct 8, 2026 with change-of-control acceleration.","CEO John S. Yu receives 190,840 RSUs ($250K) and $87.5K cash bonus for FY2024.","CSO Neil Bhomick gets 171,756 RSUs ($225K) and $50K cash bonus.","CFO Doug Samuelson gets 152,672 RSUs ($200K) and $50K bonus; VP R&D Ramachandran Murali also gets 152,672 RSUs ($200K) and $40K.","Independent directors Hyun Bae, Hansoo Keyoung, Rahul Singhvi each receive 19,084 RSUs worth $25K."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-25-018145","json":"https://secwatch.observer/filing/0001493152-25-018145.json","markdown":"https://secwatch.observer/filing/0001493152-25-018145.md","text":"https://secwatch.observer/filing/0001493152-25-018145.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1962011/000149315225018145/0001493152-25-018145-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1962011/000149315225018145/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T03:47:37.824480+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}